Science and Technology Resources

科技资源

• 批准号: 8938569
• 负责人: David Goldstein
• 金额: $ 299.99万
• 依托单位: DIVISION OF BASIC SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8938569
• 关键词: Affinity; Agreement; Antibodies; Antibody Formation; Area; Bioinformatics; Biological; Biomedical Computing; Biometry; Biotechnology; CCR; Cataloging; Catalogs; Collaborations; Computer software; Contracts; Cost Savings; Data; Databases; Development; Educational workshop; Funding; Funding Mechanisms; Gene Expression Profiling; Genomics; Individual; Information Systems; Investigation; Journals; Laboratories; Licensing; Malignant Neoplasms; Mammalian Cell; Marketing; Mediation; Microarray Analysis; Molecular; Monoclonal Antibodies; Mus; Oryctolagus cuniculus; Pathway interactions; Price; Principal Investigator; Private Sector; Production; Proteins; Proteomics; Publications; Reagent; Research; Research Personnel; Resources; Savings; Science; Scientist; Services; Technology; Technology Transfer; Training; Transfer Agreement; Validation; Work; commercialization; cost; high throughput analysis; interest; metabolomics; nano-string; new technology; next generation sequencing; novel; polyclonal antibody; programs; research study; response; tool; web site

Development of Novel Affinity Reagents. During the past fiscal year, the Office of Science and Technology Resources (OSTR) has continued to support an initiative for generating high affinity reagents to serve as tools for molecular interrogation of pathways that become altered during cancer development. Partnerships with three biotechnology companies (Beckton Dickinson, Pharmingen, Rockland Immunochemicals, and Epitomics) have led to the creation of nearly 200 novel affinity reagents, polyclonal, and monoclonal antibodies against hundreds of key cancer related targets of interest to the CCR at minimal cost to CCR investigators. These partnerships represent savings of more than one million dollars to CCR and the NCI. All of the antibody characterization data generated by participating CCR investigators is made available to the companies involved through a Web site developed in a collaboration between the OSTR and the Advanced Biomedical Computing Center (ABCC). Each company uses this data in their marketing material when the antibodies are released for commercialization. Our partnership with Epitomics is for production of rabbit monoclonal antibodies. These antibodies are known to be much more stable and have higher affinities than mouse monoclonal or rabbit polyclonal antibodies. The OSTR negotiated a contract with the company to access their antibody production pipeline at a significantly reduced cost ($5,900 versus $20,000) from the catalog price. Similar to the other collaborative programs, CCR investigators will be required to characterize the antibodies and make data available to Epitomics for validation and commercialization. The OSTR is supporting a number of protein interaction screens in mammalian cells for CCR investigators through the Laboratory of Protein Characterization at the Frederick National Lab (FNL). The OSTR continues to evaluate all commercially available platforms gene expression profiling and other high throughput genomic technologies. To make the latest advances easily accessible to CCR researchers, the OSTR has established a number of arrangements with companies providing genomic and metabolomic profiling technologies and services (Affymetrix, NanoString, Agilent, Illumina, GenUs, Qiagen, HMT, Metabolon, etc.). These agreements have led to far lower cost and an efficient and easy way for CCR investigators to access these technologies. A subsidy program has been established providing subsidies to support CCR investigator access to advanced genomic, proteomic, metabolomic, and bioinformatic technologies. This funding mechanism has helped to extend the limited research dollars available to CCR laboratories and has permitted our researchers to conduct experiments that might otherwise be cost prohibitive. Many of the funded projects have led to important publications in top tier journals. Most recently, the OSTR has been involved in CCR's efforts to access the next generation sequencing technologies, including the setting up of a new MiSeq Core in building 37, which is available to any CCR investigator. In response to CCR's rapidly growing need to manage and analyze large sets of genomic and proteomic data, the OSTR has developed several partnerships with bioinformatics companies. At significant cost savings to NCI, OSTR negotiated a variety of license agreements on behalf of all NCI researchers for universal access to sophisticated tools for bioinformatic and statistical analysis of microarray experiments, proteomic profiling studies, and genomic analysis including next generation sequencing data. In addition, the OSTR has made a number of software applications for the investigation of pathways and biological association networks available to all of NCI. The OSTR continues to assess CCR's requirements in the area of bioinformatics and biostatistics. We continue to work with the Leidos Information Systems Program to create a CCR dedicated Bioinformatics Program to provide support to CCR investigators. Support for analysis of high throughput genomic and proteomic data is being made available through this new core, which is located on the Bethesda campus.

新型亲和力试剂的开发。在过去的财政年度中，科学技术资源办公室（OSTR）继续支持一项倡议，以产生高亲和力试剂，以作为在癌症发展过程中改变途径的分子询问的工具。与三家生物技术公司（Beckton Dickinson，Pharmingen，Rockland Immununochemicals和Esporomics）的合作伙伴关系导致创建了近200个新颖的亲和力试剂，多克隆和单克隆抗体，针对CCR对CCR的数百个关键癌症与CCR成本相关的关键癌症目标。这些伙伴关系代表了CCR和NCI的一百万美元的节省。参与CCR研究人员生成的所有抗体表征数据都可以通过OSTR与高级生物医学计算中心（ABCC）合作开发的网站提供给涉及的公司。释放抗体以进行商业化时，每个公司都会在其营销材料中使用这些数据。我们与Epitomics的合作伙伴关系是生产兔子单克隆抗体。已知这些抗体比小鼠单克隆或兔多克隆抗体更稳定，并且具有更高的亲和力。 OSTR与该公司协商合同，以与目录价格相比，以大幅降低的成本（5,900美元，$ 20,000）访问其抗体生产管道。与其他协作计划类似，CCR研究人员将被要求表征抗体并使数据可用于验证和商业化。 OSTR通过Frederick National Lab（FNL）的蛋白质表征实验室（FNL）支持哺乳动物细胞中的许多蛋白质相互作用筛选。 OSTR继续评估所有市售平台基因表达分析和其他高通量基因组技术。为了使CCR研究人员易于获得最新进展，OSTR已与提供基因组和代谢组分析技术和服务的公司建立了许多安排（Affymetrix，Nanostring，Agilent，Agilent，Illumina，Illumina，Genus，Qiagen，Qiagen，HMT，Metabolon等）。这些协议导致了CCR调查人员访问这些技术的高效，简便的方法。已经建立了一项补贴计划，提供补贴，以支持CCR研究者访问高级基因组，蛋白质组学，代谢组和生物信息学技术。这种资金机制有助于扩大CCR实验室可用的有限的研究资金，并允许我们的研究人员进行实验，否则可能是成本高昂的。许多资助的项目导致了顶级期刊的重要出版物。最近，OSTR参与了CCR访问下一代测序技术的努力，包括在37号建筑物中建立了新的Miseq核心，任何CCR调查员都可以使用。为了响应CCR管理和分析大量基因组和蛋白质组学数据的迅速增长的需求，OSTR与生物信息学公司建立了多种合作伙伴关系。 OSTR以大幅节省的成本节省了，代表所有NCI研究人员就多种访问复杂的工具进行了多种许可协议，以对微阵列实验，蛋白质组学分析研究以及基因组分析进行生物信息学和统计分析，并进行了统计分析，包括下一代测序。此外，OSTR为所有NCI提供的途径和生物协会网络的调查提供了许多软件应用程序。 OSTR继续评估CCR在生物信息学和生物统计学领域的要求。我们继续与Leidos Information Systems计划合作，创建CCR专用的生物信息学计划，以为CCR调查人员提供支持。支持分析高吞吐量基因组和蛋白质组学数据的支持，该数据通过位于贝塞斯达校园的新核心提供。